Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2012 Oct;11(10):763-76. doi: 10.1038/nrd3794.

Targeting IL-17 and TH17 cells in chronic inflammation.

Author information

1
Department of Clinical Immunology and Rheumatology, University of Lyon 1, Hôpital Edouard Herriot, 5 Place d'Arsonval, 69437 Lyon, France. pierre.miossec@univlyon1.fr

Abstract

The key role of interleukin-17 (IL-17) and T helper 17 (T(H)17) cells in tissue inflammation, autoimmunity and host defence led to the experimental targeting of these molecules in mouse models of diseases as well as in clinical settings. Moreover, the demonstration that IL-17 and T(H)17 cells contribute to local and systemic aspects of disease pathogenesis, as well as the finding that the IL-17-T(H)17 cell pathway is regulated by IL-23, prompted the identification of inhibitors. These inhibitors include biotechnology products that target IL-23 as well as the leading member of the IL-17 family, IL-17A, and one of its receptors, IL-17 receptor A. Several clinical trials of these inhibitors are underway, and positive results have been obtained in psoriasis, rheumatoid arthritis and ankylosing spondylitis. This Review focuses on the current knowledge of the IL-17-T(H)17 cell pathway to better understand the positive as well as potential negative consequences of targeting them.

PMID:
23023676
DOI:
10.1038/nrd3794
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center